From the "going out of the tumor" to the anti-cancer story of people around, the tragedy caused by cancer in reality is often embarrassing and talk about cancer. From the results of large-scale promotion of early screening in Europe and the United States in the past few decades, if the prevention and timely treatment, the cancer cure rate will be greatly improved. In recent years, intestinal cancer has been the second most common cancer in China. Colon cancer is a typical rich cancer. With the gradual increase of GDP, the incidence of intestinal cancer has increased by 4.2% per year, like Hong Kong, Macao and Taiwan. Singapore, the incidence of intestinal cancer ranked first. Because there are no obvious symptoms in the early stage, they are often mistaken for other digestive diseases and neglected, and most people in the country are difficult to accept the screening method of colonoscopy, thus missing the best treatment time and causing tragedy.
Not long ago, Nuohui Health teamed up with Zhongan Insurance to launch the first domestic prevention of bowel cancer insurance--"Yi Weiqing" (ie Chang Weiqing). As the first screening genetic testing service operated by China's first home, Chang Weiqing is a brand new non-invasive, painless, non-invasive intestinal cancer screening. Using differential DNA analysis technology, it can detect the presence of abnormal DNA, recognition and DNA lesions associated with intestinal cancer or precancerous lesions, and early detection of advanced adenomas and precancerous lesions with a diameter of more than 1 cm, early detection of early intestinal cancer gene mutations, early detection, early diagnosis, early treatment.
Hangzhou Nuohui Health Technology Co., Ltd. (Nuohui Health) is a research service company dedicated to early screening of cancer. Established in 2013, after two years of research and development, the company officially launched its products at the end of 2015. Immediately completed a $20 million Series A financing, the financing was led by Junlian Capital, and Softbank China followed.
According to Zhu Yeqing, CEO of Nuohui Health, the number of early screening users for bowel cancer is expected to reach 500,000 to 1 million in 2018. An early screening product for gastric cancer will be launched in September this year, and early screening products for breast and cervical cancer in women are planned for 2017.
Organic Intermediates N-Hydroxy Succinimide,Pharmaceutical Intermediates 2 3-Dichloroaniline,Trifluoromethanesulfonic Anhydride,3-Chloroaniline Colorless Liquid
Shandong YingLang Chemical Co.,Ltd , https://www.sdylhgtrade.com